[1]张学玲,陈庆峰,姜丹丹,等. 乳癌病人血清鸢尾素的表达及其临床意义[J].青岛大学学报(医学版),2018,54(03 ):302-304,308.[doi:10.11712/jms201803011]
 ZHANG Xueling,CHEN Qingfeng,JANG Dandan,et al. THE EXPRESSION OF SERUM IRISIN IN BREAST CANCER PATIENTS AND ITS CLINICAL SIGNIFICANCE[J].JOURNAL OF QINGDAO UNIVERSITY (MEDICAL SCIENCES),2018,54(03 ):302-304,308.[doi:10.11712/jms201803011]
点击复制

 乳癌病人血清鸢尾素的表达及其临床意义()
分享到:

《青岛大学学报(医学版)》[ISSN:2096-5532/CN:37-1217/R]

卷:
第54卷
期数:
2018年03 期
页码:
302-304,308
栏目:
出版日期:
2018-05-29

文章信息/Info

Title:
 THE EXPRESSION OF SERUM IRISIN IN BREAST CANCER PATIENTS AND ITS CLINICAL SIGNIFICANCE
作者:
 张学玲陈庆峰姜丹丹宋真曲慧莉李福年
 青岛大学附属医院乳腺诊疗中心,山东 青岛 266100
Author(s):
 ZHANG Xueling CHEN Qingfeng JANG Dandan SONG Zhen QU Huili LI Funian
 Breast Clinic, The Affiliated Hospital of Qingdao Uniwersity, Qingdao 266100, China
关键词:
 乳房肿瘤鸢尾素淋巴转移Ki-67抗原
Keywords:
 breast neoplasms irisin lymphatic metastasis Ki-67 antigen
分类号:
R737.9
DOI:
10.11712/jms201803011
文献标志码:
A
摘要:
 目的 探讨血清鸢尾素(Irisin)在乳癌病人中的表达及其临床意义。
方法 收集青岛大学附属医院乳腺诊疗中心46例乳腺浸润性癌病人、30例乳腺纤维腺瘤病人及同期在本院接受体检的12例健康者血液标本。采用ELISA方法检测3组空腹血清中Irisin表达,分析3组之间以及不同病理特征乳癌病人血清Irisin表达差异。
结果 乳腺浸润性癌组、乳腺纤维腺瘤组、健康人组的血清Irisin表达水平分别为(2.15±0.53)、(3.08±0.44)、(3.26±0.34) mg/L,乳癌病人血清Irisin水平显著低于乳腺纤维腺瘤组和健康人组(t=8.03、6.93,P<0.01);乳腺纤维腺瘤组的血清Irisin水平与健康人组比较差异无显著性(P>0.05);淋巴结转移乳癌病人血清Irisin表达水平明显低于无淋巴结转移者(t=2.38,P<0.05);Ki67>20%的乳癌病人血清Irisin表达水平明显低于Ki67≤20%者(t=2.89,P<0.05)。
结论 血清Irisin表达水平与乳癌增殖及淋巴结转移密切相关,检测血清Irisin可能为了解乳癌的发生发展机制、判断预后提供参考。
Abstract:
 Objective To investigate the expression of serum irisin in breast cancer patients and its clinical significance.
Methods We collected blood samples from 46 patients with breast invasive carcinoma and 30 patients with breast fibroadenoma in Breast Clinic, The Affiliated Hospital of Qingdao University, as well as 12 healthy individuals undergoing physical examination at the same hospital during the same period. ELISA was used to determine the expression of irisin in the fasting serum of the three groups, and the differences in serum irisin expression were analyzed between the three groups and breast cancer patients with different pathological characteristics.
Results The expression levels of serum irisin in the breast invasive carcinoma group, the breast fibroadenoma group, and the healthy group were (2.15±0.53), (3.08±0.44), and (3.26±0.34) mg/L, respectively. The level of serum irisin in the breast invasive carcinoma group were significantly lower than those in the breast fibroadenoma group and the healthy group (t=8.03 and 6.93, both P<0.01). There was no significant difference in the serum irisin level between the breast fibroadenoma group and the healthy group (P>0.05). The expression level of serum irisin in breast cancer patients with lymph node metastasis was significantly lower than that in breast cancer patients without lymph node metastasis (t=2.38,P<0.05). The expression level of serum irisin in breast cancer patients with Ki67>20% was significantly lower than that in breast cancer patients with Ki67 ≤20% (t=2.89,P<0.05).
Conclusion The expression level of serum irisin is closely related to breast cancer proli-
feration and lymph node metastasis. The determination of serum irisin may provide a reference for understanding the development and progression of breast cancer and its prognostic prediction.
更新日期/Last Update: 2018-06-05